Anticoagulation Timing in Acute Stroke With Atrial Fibrillation According to Chronic Kidney Disease: The OPTIMAS Trial
Antikoagulationszeitpunkt bei akutem Schlaganfall mit Vorhofflimmern nach chronischer Nierenerkrankung: Die OPTIMAS-Studie
Stroke · 2025-08 · 56 (8) · 1970-1979
DOI: 10.1161/strokeaha.125.051457 ↗Auf einen Blick
In der OPTIMAS-Subgruppenanalyse gab es bei Patient:innen mit und ohne CKD keinen Unterschied zwischen früher und verzögerter DOAC-Initiierung nach akutem ischämischem Schlaganfall.
Fragestellung
Verändert CKD den Effekt einer frühen im Vergleich zu einer verzögerten DOAC-Initiierung nach akutem ischämischem Schlaganfall bei Vorhofflimmern?
Methode
Multizentrische, randomisierte, parallele, offene Studie mit verblindeter Endpunktbewertung; 100 UK-Kliniken; Randomisierung 1:1 zu früher (innerhalb 4 Tage) oder verzögerter (Tag 7–14) DOAC-Initiierung.
Ergebnisse
3.601 Patient:innen, davon 543 mit CKD. Primärer Endpunkt: 97 (3,2 %) in der Normalnierenfunktion-Gruppe und 19 (3,5 %) in der CKD-Gruppe. Kein Unterschied: OR 1,01 (95 %-KI 0,67–1,51) vs. OR 0,90 (95 %-KI 0,36–2,25); P-Interaktion=0,822.
Schlussfolgerung der Autor:innen
Die Autor:innen schließen, dass CKD die Wirkung einer frühen gegenüber einer verzögerten DOAC-Initiierung nach akutem ischämischem Schlaganfall nicht verändert.
Kernaussagen
- 3.601 Patient:innen, 543 mit CKD
- Kein Unterschied im primären Endpunkt zwischen früher und verzögerter DOAC-Initiierung
- Keine Effektmodifikation durch CKD bei den Sekundärendpunkten
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Multizentrische Studie in der Zeitschrift Stroke, 2025-08. Verfasst von Philip S Nash und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Brain Repair and Rehabilitation, Stroke Research Centre, University College London Queen Square Institute of Neurology, United Kingdom …. Hauptthemen laut MEDLINE: Atrial Fibrillation, Renal Insufficiency, Chronic, Anticoagulants, Ischemic Stroke. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Schlaganfall
Abstract (Originalsprache)
BACKGROUND: Patients with chronic kidney disease (CKD) are at increased risk of ischemic stroke (IS) and intracerebral hemorrhage, so the safety and efficacy of early direct oral anticoagulant (DOAC) initiation in those with CKD are of clinical relevance. METHODS: OPTIMAS (Optimal Timing of Anticoagulation After Acute Ischemic Stroke With Atrial Fibrillation) was a multicenter, randomized, parallel-group, open-label trial with blinded outcome assessment, recruiting patients with IS and atrial fibrillation from 100 UK hospitals between 2019 and 2024. Participants were randomized 1:1, stratified by stroke severity, to early (within 4 days of onset) or delayed (at days 7–14) DOAC initiation. CKD was defined as a past medical history of known CKD, collected according to trial protocol as part of the case report form. For this prespecified subgroup analysis, the trial cohorts were classified according to the presence or absence of CKD. Whether CKD modified the treatment effect of early DOAC initiation was determined by fitting mixed effects logistic regression models with interaction terms between CKD and treatment group. The primary outcome was a composite outcome of recurrent IS, symptomatic intracranial hemorrhage, and systemic arterial embolism. Key secondary outcomes included the individual components of the primary outcome and all-cause mortality. RESULTS: We included 3601 patients (mean age, 78±10 years; 45% female), 543 with CKD. There were 116 primary outcome events: 97 (3.2%) in the normal kidney function group and 19 (3.5%) in the CKD group. There was no difference between early and delayed DOAC initiation for the primary outcome in either the normal kidney function group (odds ratio, 1.01 [95% CI, 0.67–1.51]) or the CKD group (odds ratio, 0.90 [95% CI, 0.36–2.25]; P interaction =0.822). Similarly, for the secondary outcomes, we detected no modification of the treatment effect according to CKD ( P interaction values of 0.637, 0.386, and 0.107 for IS, symptomatic intracranial hemorrhage, and all-cause mortality, respectively). CONCLUSIONS: Our findings suggest that CKD does not modify the effects of early versus delayed DOAC initiation after acute IS. Based on these results, early DOAC initiation should not be withheld in patients with CKD. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03759938.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Brain Repair and Rehabilitation, Stroke Research Centre, University College London Queen Square Institute of Neurology, United Kingdom (P.S.N., L.A., J.G.B., S.M., D.J.W.).
- Comprehensive Clinical Trials Unit, Institute of Clinical Trials and Methodology (H.-M.D., N.A., M.B., K.B., E.B., E.C., M. Chau, M. Cullen, C.J.D., R.F., A.G., R.H., A.J., I.M., A.N., J.P., H.S., T.V., N.F.).
- Department of Haematology, Cancer Institute, University College London Hospitals (H.C.).
- University Department of Geriatric Medicine FELIX PLATTER, Neurology and Neurorehabilitation, University of Basel, Switzerland (S.T.E.).
- Medical Sciences Division, University of Oxford, United Kingdom (G.A.F.).
- Royal Devon & Exeter Hospital, University of Exeter Medical School, United Kingdom (M.J.).
ORCID-Profile: Philip S Nash, Hakim-Moulay Dehbi, Norin Ahmed, Maryam Balogun, Ekaterina Bordea, Hannah Cohen, Stefan T Engelter, Robert Fenner, Gary A Ford, Archana Jayanthi, Gregory Y H Lip, Bo Norrving, Nikola Sprigg, Tishok Vanniyasingam, David C Wheeler, David J Werring
Zitieren
APA
Nash, P. S., Dehbi, H. M., Ahmed, N., Arram, L., Best, J. G., Balogun, M., Bennett, K., Bordea, E., Caverly, E., Chau, M., Cohen, H., Cullen, M., Doré, C. J., Engelter, S. T., Fenner, R., Ford, G. A., Gill, A., Hunter, R., James, M., …, & OPTIMAS Investigators (2025). Anticoagulation Timing in Acute Stroke With Atrial Fibrillation According to Chronic Kidney Disease: The OPTIMAS Trial. Stroke, 56(8), 1970-1979. https://doi.org/10.1161/strokeaha.125.051457
Vancouver
Nash PS, Dehbi HM, Ahmed N, Arram L, Best JG, Balogun M, et al. Anticoagulation Timing in Acute Stroke With Atrial Fibrillation According to Chronic Kidney Disease: The OPTIMAS Trial. Stroke. 2025;56(8):1970-1979. doi:10.1161/strokeaha.125.051457
BibTeX
@article{Nash2025,
author = {Nash, Philip S and Dehbi, Hakim-Moulay and Ahmed, Norin and Arram, Liz and Best, Jonathan G and Balogun, Maryam and Bennett, Kate and Bordea, Ekaterina and Caverly, Emilia and Chau, Marisa and Cohen, Hannah and Cullen, Mairead and Doré, Caroline J and Engelter, Stefan T and Fenner, Robert and Ford, Gary A and Gill, Aneet and Hunter, Rachael and James, Martin and Jayanthi, Archana and Lip, Gregory Y H and Massingham, Sue and Murray, Macey L and Mazurczak, Iwona and Ndoutoumou, Amalia and Norrving, Bo and Philip, Jenny and Sims, Hannah and Sprigg, Nikola and Vanniyasingam, Tishok and Freemantle, Nick and Wheeler, David C and Werring, David J and OPTIMAS Investigators, OPTIMAS Investigators},
title = {Anticoagulation Timing in Acute Stroke With Atrial Fibrillation According to Chronic Kidney Disease: The OPTIMAS Trial},
journal = {Stroke},
year = {2025},
volume = {56},
number = {8},
pages = {1970--1979},
doi = {10.1161/strokeaha.125.051457}
}
EUVIMED